First in Class Rivaroxaban vs Apixaban Course
hosted byConnect Educate Impact (CEI)First in Class Rivaroxaban vs Apixaban Course is organized by Connect Educate Impact (CEI).
Initial Release Date: May 11, 2022
Planned Expiration Date: May 11, 2025
Description:
While Direct Oral Anticoagulants (DOACs) such as apixaban and rivaroxaban are recommended for patients with atrial fibrillation, there hasn't been evidence directly comparing them. Join us as we discuss their differences and guide your selection of a DOAC for minimized side effects and increased efficacy in your patients.
Objectives:
Upon successful completion of this application-based course, participants should be able to:
• Describe key aspects of the Association of Rivaroxaban vs. Apixaban with Major Ischemic or Hemorrhagic Events in patients with Atrial Fibrillation Study
• Compare rates of hemorrhagic events between patients from the Association of Rivaroxaban vs. Apixaban with Major Ischemic or Hemorrhagic Events in patients with Atrial Fibrillation study
• Compare rates of ischemic events between patients from the Association of Rivaroxaban vs. Apixaban with Major Ischemic or Hemorrhagic Events in patients with Atrial Fibrillation study
• Evaluate limitations discussed in the Association of Rivaroxaban vs. Apixaban with Major Ischemic or Hemorrhagic Events in patients with Atrial Fibrillation Study
• Apply the findings from the Association of Rivaroxaban vs. Apixaban with Major Ischemic or Hemorrhagic Events in patients with Atrial Fibrillation study in providing care to patients with atrial fibrillation
